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Abstract
Recent data shows that HIV-1 is characterised by variation in viral virulence factors that is heritable between infections,
which suggests that viral virulence can be naturally selected at the population level. A trade-off between transmissibility
and duration of infection appears to favour viruses of intermediate virulence. We developed a mathematical model to
simulate the dynamics of putative viral genotypes that differ in their virulence. As a proxy for virulence, we use set-point
viral load (SPVL), which is the steady density of viral particles in blood during asymptomatic infection. Mutation, the
dependency of survival and transmissibility on SPVL, and host effects were incorporated into the model. The model was
fitted to data to estimate unknown parameters, and was found to fit existing data well. The maximum likelihood estimates
of the parameters produced a model in which SPVL converged from any initial conditions to observed values within 100–
150 years of first emergence of HIV-1. We estimated the 1) host effect and 2) the extent to which the viral virulence
genotype mutates from one infection to the next, and found a trade-off between these two parameters in explaining the
variation in SPVL. The model confirms that evolution of virulence towards intermediate levels is sufficiently rapid for it to
have happened in the early stages of the HIV epidemic, and confirms that existing viral loads are nearly optimal given the
assumed constraints on evolution. The model provides a useful framework under which to examine the future evolution of
HIV-1 virulence.
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Introduction
The median time between HIV-1 seroconversion and progres-
sion to symptomatic Acquired Immune Deficiency Syndrome
(AIDS) is approximately 10 years [1]. However, there is
considerable variation in this rate of progression, with substantial
proportions of infected individuals progressing to AIDS in less
than 5 years, or remaining AIDS-free after 20 years. Explaining
this variability is an important goal of HIV pathogenesis research.
Many cofactors which influence time to AIDS have been identified
e.g. host genetics [2], host age [1], and recently viral factors have
been implicated [3–10].
In this paper we explore the extent to which viral factors which
influence virulence, changing from one infected individual to the
next, may have evolved under natural selection in the early phase
of HIV-1’s history. Between-host selection, leading to changes in
the virulence of HIV-1, has potential major implications for the
number of human life years affected.
Virulence is often defined as the excess mortality of the host
which occurs as a result of infection with a pathogen. In the case of
HIV the excess mortality is nearly 100%, so virulence can be
better defined by the reciprocal of the time from infection to death,
or time to AIDS. However, since this can only be defined at the
host’s death, we use set-point viral load (SPVL) as a proxy for
virulence. This refers to the relatively stable density of virions in
the blood which characterises asymptomatic infection. There is
considerable population level variation in SPVL, in spite of its
relative stability within the individual [11]. SPVL is widely used as
a prognostic indicator for AIDS, as individuals with a higher
SPVL have a higher rate of CD4+ cell decline, and they tend to
progress more rapidly to AIDS [12,13] and die sooner as a
consequence [14]. As a result of its relative constancy during
asymptomatic infection, SPVL can be measured at a wide range of
time points in an individual’s infection [15].
A simple conceptual model of how SPVL may evolve by
between-host natural selection (i.e. selection for the more
transmissible genotypes) requires consideration of the transmission
potential of individuals of different SPVL. The transmission
potential, defined as the product of duration of infection and
infection rate, increases with either component of this product. A
positive correlation between SPVL and transmission rate has been
convincingly demonstrated within heterosexual couples with
initially discordant serostatus [16–18]. Since there is also a
negative correlation between SPVL and duration of asymptomatic
infection [12], there is therefore a trade-off between duration of
and transmission rate during asymptomatic infection. Previous
work has quantified this trade-off to suggest that SPVL most
commonly observed in infections maximise the transmission
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potential, suggesting that the distribution of SPVL was shaped by
natural selection [19].
Natural selection requires that a trait has heritability from one
generation to the next, in addition to variation and differential
reproductive success. A number of recent studies have identified
and quantified this heritable component of SPVL variation which
is maintained from one infection to the next [3,5,6,9,10].
Recent studies from the Netherlands [20] and Italy [21] have
found that the mean log10 SPVL has increased over the recorded
history of an HIV-infected cohort, and the rate of CD4+ cell
decline has increased. However different transmission groups have
demonstrated different patterns of evolution of SPVL. In the initial
stages of the epidemic (mid 1980s) injecting drug users showed
slower CD4+ declines than heterosexuals or men having sex with
men, but this difference decreased over the subsequent decade
[21]. A study with similar methodology in Switzerland found
stable virulence over the same time period [22]. This suggests that
such trends may be area- and risk-group specific. In two studies
showing an increase, the levels of SPVL in the earlier time points
are lower [20,21] than those which are optimal for transmission
[19]. Various studies of the rate of CD4+ decline also suggest an
increasing virulence [23,24]. A study of the in vitro replicative
fitness of viruses sampled at different time points reported a
decrease in replicative fitness over the course of the epidemic in
Amsterdam [25] although a subsequent study of the same city
which controlled for time of seroconversion found an increase
[26]. Overall, observational results on changing virulence are
inconclusive, though they suggest either an equilibrium or a slow
increase in that direction.
The lack of evidence for consistent population level trends in
SPVL evolution [21,22] suggests a) the global distribution of SPVL
has stabilised at an equilibrium level; b) the rate of evolution is very
slow or c) the distribution of SPVL is determined by factors which
do not evolve. However, we think c) unlikely, first due to the
observations on the heritability of SPVL described above, and
second because there is evidence for evolution of SPVL occurring
in particular areas or risk groups [20,21].
To address the expected dynamics of SPVL evolution, we
developed and analysed a deterministic mathematical model of
between-host transmission and evolution incorporating known
parameters linking SPVL to the duration of infection and the rate
of transmission. The broad aim was to investigate the hypothesis
that viral genotypes of intermediate virulence are naturally
selected by transmission [19].
The primary of aim of this study was to use the observed
distribution of SPVL to estimate the quantities of unknown host
and viral factors which affect the process of between-host
evolution. Comparing the model to data allowed us to calculate
the likelihood of the unknown parameters.
The secondary aim was to assess whether the model, under
these parameter estimates, allows convergence of the SPVL
distribution towards an intermediate level, or at least to slowly
changing levels consistent with observational studies, regardless of
the virulence of the founding strain, and whether this can occur
within a plausible timescale. The estimated time of origin of HIV-
1 is before the most recent common ancestor, which has been
dated to 1908 with 95% confidence interval 1884–1924 [27]. If
evolution has occurred between the founding strain and current
infections then it has occurred over a period of ,100 years.
Results
We modelled the dynamics of putative genotypes of HIV-1
which differ from one another in their mean log10 SPVL. SPVL
was assumed to vary as a result of both host and virus factors.
These genotypes differ in their reproductive success as a result of
the dependency of duration of asymptomatic infection and
transmission rate on SPVL. Their prevalences change over time
through competition for susceptible individuals in a constant
population.
The model is formulated as a standard HIV epidemic model in
which different viral strains or genotypes compete. Virulence is
considered as a one-dimensional trait, with each genotype
represented by a point on the one-dimensional spectrum of
increasing virulence. When a person is infected by a virus of a
given genotype, the infection is characterised by a SPVL which
reflects the virulence, but also other non-viral factors. When
transmitted, the virus can also mutate to higher or lower levels of
virulence.
The model encodes the natural history of infection. After
infection, individuals experience a brief period of highly infectious
acute stage, after which they progress to chronic asymptomatic
infection. Their SPVL determines both the duration and
infectiousness of this asymptomatic stage, after which their viral
load and infectiousness increases again as they progress to AIDS
and death. Individuals are assumed to engage in serially
monogamous partnerships; a realistic description of the sexual
network was not an aim of this study.
For the sake of parsimony, we focused on relatively simple
mathematical models with minimal sets of parameters, and thus
left some important questions open for further study. In particular,
we did not explore the effect of population structure, stochastic
fluctuations, differences between subtypes, superinfection, and
founder effects, and we considered only the situation of natural,
untreated infection, thus appropriate to describing the evolution of
the virus prior to the widespread adoption of antiretroviral
therapy. We also did not address the question of conflicting
directions of selection at the within and between host level,
describing in-host changes in virulence instead as random drift.
We hope to address these important questions in future work.
Author Summary
Recent studies have suggested that virulence in HIV-1 is
partly a characteristic of the virus which is carried from one
infection to the next. An infection with intermediate
virulence will produce more transmissions during the
infectious lifetime because it optimises the trade-off
between rate of transmission and duration of infection.
Natural selection acts on the heritable variation to increase
the relative prevalence of strains with intermediate
virulence. In this study we model the evolution of
virulence in the viral population as these more successful
strains are preferentially transmitted. We fit this model to
data from transmitting couples, and find that the model
fits the data well. We use this fit to estimate the
contribution of the host and the virus to virulence, which
complements recent estimates of the heritability of
virulence. We also estimate the rate at which the viral
determinants of virulence evolve between infections, and
this provides predictions for how rapidly the virulence of
HIV-1 evolves in a population. We suggest that natural
selection on transmissibility results in substantial evolution
of virulence in the population. This is sufficiently rapid for
virulence to have reached current levels over the available
timescale of the human epidemic.
Modelling the Evolution of HIV-1 Virulence
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Variance decomposition
A useful practical and conceptual approach to interpreting
various influences acting on SPVL is to decompose the total
observed variance, sP
2, into its components, genotypic, mutational
and environmental variance (sG
2, sM
2, and sE
2) [28].
sP
2~sG
2zsM
2
viral
zsE
2
host
heritable non-heritable
ð1:1Þ
Genotypic variance sG
2 refers to differences in SPVL between
infected individuals caused by viral factors which are preserved
from one infection to the next. Environmental variance, sE
2, refers
to any source of SPVL variance external to the virus. Host factors
e.g. age [29], sex [30] and host genotype [31], in particular HLA
type [2] contribute significantly to variation in SPVL between
individuals, and there may be other human and non-human
covariates of SPVL e.g. antigenic stimulation [32]. All of these
factors, extrinsic to the virus, contribute to sE
2 in our terminology.
Mutational variance, sM
2, accounts for changes in the viral
virulence genotype which result from mutation of the virus
between one generation and the next (i.e. one infected host and the
next) as a result of within-host replication and selection of the
virus. Since the viral determinants of SPVL are not currently
known, this cannot be related to the nucleotide substitution
rate.The mutational standard deviation, sM, is simply the
expected difference in the viral component of SPVL between an
index and a secondary infection.
Heritability, h2, which has been quantified in previous studies,
was defined as the fraction of variance explained by shared viral
factors within a transmitting couple [6,33]. We estimate h2 as the
proportion of variance in SPVL explained by heritable viral
genetic factors:
h2~
sG
2
sP2
ð1:2Þ
Alternative definitions of heritability, including the proportion of
variance in SPVL explained by the SPVL of the index case, and
the proportion explained by viral factors, are discussed and
estimated in Text S1.
In this study, we aim to separately estimate sM
2 and sE
2, and
thus gain a better estimate of the extent of viral factors in
individual infections, and the parameters needed to predict
evolution.
Model fitting and parameter estimation
The primary aim of the analysis was to quantify the effects of
host and virus on variation in SPVL. The values of the
environmental and mutational standard deviations (sE and sM)
were estimated using a maximum likelihood approach. Since the
model predicts not just the distribution of SPVL, but how they
change from one infection to the next, the model could predict the
observed SPVL in both index and recipient partners in
transmitting couples.
Figure 1 shows the likelihood surface for the environmental
and mutational standard deviations (sE and sM), and the bivariate
confidence bounds. The maximum likelihood estimates are
sM=0.12 (95% confidence interval 0.00 to 0.39) and sE=0.66
(95% confidence interval 0.47–0.94). The estimates with highest
mutational standard deviation within the 95% confidence bounds
are sM=0.39 and sE=0.55 referred to later as the most mutable
plausible scenario. Further details of the likelihood surface are
given in Figure S2. The diagonal nature of the region of high
likelihood in Figure 1 (or better viewed in Figure S2) indicates a
trade-off between the two parameters in terms of the quality of
model fit.
Figure 2 shows the quality of fit of the model to the distribution
of SPVL in index partners and recipients in transmitting couples,
and the estimated heritability was 26% (compared to 27% in a
previous statistical analysis of these couples [6]). We conclude that
the model describes the data well. The distribution and heritability
of set-point viral load is well described by a multi-strain model of
HIV-1 virulence evolution.
Convergence of SPVL distribution
Having derived maximum likelihood estimates of parameters
from an equilibrium solution to the model, the dynamics of
genotype competition were then simulated numerically in order to
assess whether or not convergence would occur under those
parameter values, and on what timescale the convergence would
occur.
The evolution of the SPVL distribution is shown in Figure 3.
Regardless of whether the virulence of the founding genotype was
high or low, the SPVL evolved towards an intermediate level with
a mean log10 SPVL of 4.5.
This convergence on intermediate SPVL values also occurred
when other combinations of parameter values in the region of high
likelihood (Figure 1) were used instead. The rate of convergence
was positively related to sM, as shown in Figure 4(a), where the
maximum likelihood prediction is compared to the most mutable
plausible scenario. Convergence towards intermediate virulence
occurred in approximately 150 years under the maximum
likelihood values. There was still change in the mean after this
time but runs beginning with high or low virulence converge
around this time point. The same point was reached in 50 years
under the most mutable plausible scenario.
The heritability was also calculated over time (Figure 4(b)) and
under maximum likelihood values of sE and sM this reached
equilibrium at 26%, which is consistent with previous studies
[3,5,6,9,10]. Further details of the heritability and variance at
equilibrium are given in Figures S3 and S4.
In order to examine how changes in mean log10 SPVL are
related to the stage of the epidemic, we examined the effect of
proportion infected over time. The effect was most evident when
the founding virulence closely matched the equilibrium virulence
(Figure 5(b)). During the epidemic growth phase the mean
virulence increased to levels above the optimum, and then
returned to the optimum as the proportion infected reached
equilibrium.
We varied the founding virulence to investigate its effect on rate
of convergence (Figure 6(a)). This had a marked effect on how
quickly the mean log10 SPVL reached equilibrium (4.52 log10
SPVL). When the founding genotype had mean 4.5 log10 SPVL,
equilibrium with regard to the mean was reached very quickly, and
the more different the SPVL of the founding genotype, the longer
the time to convergence. A similarly rapid convergence is seen if all
genotypes had equal prevalence at the start of the run. The mean
underwent little change (data not shown) but the variance rapidly
decreased as the most successful genotype, already present in the
population, began to dominate (Figure 6(b)).
Finally, we investigated the sensitivity of our findings to the
choice of parameter values determining the dependencies of
infectiousness and duration of asymptomatic infection on SPVL.
These parameters were previously estimated from datasets from
Amsterdam and Zambia [19]. Here, we tested the sensitivity to
Modelling the Evolution of HIV-1 Virulence
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those estimates by bootstrapping these datasets, refitting the
parameters each time and calculating the corresponding maxi-
mum likelihood estimates of sE and sM. Details of the method are
in Text S1 and Table S2. The resulting maximum likelihood
estimates (Table S3 and Table S4) are similar to those from the
principal analysis (Figure 1).
Discussion
In this paper, we developed a multi-strain evolutionary
epidemiological model of HIV-1 virulence, and showed that it
could accurately reproduce observations on the distribution of viral
load and its heritability in transmitting couples (Figure 2). We were
able to estimate the proportion of variance in set-point viral load
explained by viral genetic factors (26%, 12(sE
2+sM2)/sP2), and
separately how much these factors change (‘mutate’) from one
infection to the next. Our best estimate is that virulence changes
slowly towards an evolutionary optimum over decades, but we
cannot rule out faster changes (Figure 4 and Figure 6).
Our aim here was to develop a simple, parsimonious ‘broad-
brush’ model to understand the principles of HIV-1 virulence
evolution in a generalised epidemic using data currently available.
Most of the parameters were derived from Sub-Saharan African
studies (Table S1), suggesting that the model has most direct
relevance for this context. This is our intention, as this is where most
of the adaptation of HIV-1 to the human population has occurred.
The parameters determining the curve of survival from disease
progression were derived from European data, and since these data
predate antiretroviral therapy they are not expected to differ
substantially from parameters derived from Sub-Saharan Africa.
We do not expect the epidemic in other contexts to differ
drastically. Two studies which have observed a change in virulence
Figure 1. Likelihood surface for the environmental and mutational standard deviation (sE and sM). The maximum likelihood estimate is
represented by the red point, and the regions of 50%, 95% and 99.9% confidence in orange, yellow and green respectively. The method for
calculating confidence intervals is given in Text S1 equation (5.4).
doi:10.1371/journal.pcbi.1002185.g001
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in the Netherlands [20] and Italy [21] appear to support our
hypothesis as the virulence in both situations has risen from a sub-
optimal level towards equilibrium, as predicted in our model. The
same trend was not seen in Switzerland [22], however, and further
work is required to apply the model rigorously to the European
context with a view to explaining these trends. More realistic
predictions will require more detailed models, and by necessity
more data. We list some factors that could be included in a more
detailed analysis.
Describing the differences between subtypes of HIV-1 seems
like one of the biggest challenges to the model presented here. We
considered virulence evolution on a single dimension of low-to-
high, with single functions describing the relationship between
viral load, infectiousness and duration of asymptomatic infection.
HIV-1 subtypes in fact differ in their transmission parameters
independently of their differences in SPVL [4,7,8]. Subtype A
shows a slower disease progression when compared to other
subtypes [34]. More specifically, data from the Rakai study
showed that subtype A infection results in slower disease
progression than subtype D even though the distribution of SPVL
is the same [4,7]. From the same cohort it was shown that subtype
A is also more transmissible than subtype D even when viral load
and other confounding variables are controlled for in a regression
[35]. Subtype A is therefore fitter than D in both duration and
transmissibility, and the evolutionary hypothesis would predict the
gradual replacement of subtype D by subtype A, which has been
observed in Uganda [36] and Greece [37]. Other noteworthy
trends include the dominance of subtype C in southern Africa
[38], which may be a result of an extended period of high viraemia
in primary infection [39]. Taken together, these findings strongly
suggest that HIV-1 virulence can change in ways not fully reflected
by set-point viral load, and thus that more data are needed to
identify other appropriate surrogate measures (or determinants) of
virulence. More generally, the theoretical challenge is then to
explain in terms of these other determinants of infectiousness and
survival, how differences in virulence are maintained in different
viral subtypes.
There are a number of other directions in which our model
could be developed. In this study the mutational variance, the
extent to which the viral genotype changed from one infection to
the next, was considered independent of the age of infection (AOI).
At first, this may seem a paradoxical choice, since mutation which
occurs between hosts must be the result of mutations and selection
occurring within the infected host. It would reasonable to suggest
that the size of between-host mutation is positively related to the
AOI, since nucleotide divergence from the founding strain has
been shown to occur at a constant rate during infection [40]. If this
were the case, the between-host mutation rate would be the same
regardless of the generation time and consequently of the virulence
of the virus. However, a study of within-host evolution over time
found that the rate of divergence from the founding genotype was
positively correlated with viral load [41], suggesting that higher
virulence infections diverge more rapidly. A model with a
mutational variance independent of the AOI allows for this, as a
higher virulence virus will have more generations in a given
amount of time and therefore more between-host mutation events.
An accurate functional representation of mutational variance as
a function of AOI thus requires more detailed understanding than
seems currently possible. To resolve this, and for the sake of
parsimony, we assume that the two effects described above cancel
each other out, and thus that the mutational variance is
independent of AOI. To test the sensitivity to this assumption,
we changed the model to include AOI-dependent mutational
variance (linearly increasing as a function of time), and the results
were qualitatively and quantitatively similar (data not shown).
An additional problem with this model is that the data to which
the model is fitted consists of transmission pairs, for most of whom
the age of infection at which transmission occurs is unknown.
Assuming an AOI-independent mutational variance considerably
reduces the complexity of the analysis. There is however little
doubt that extending the model to include a more detailed
description of within-host processes and also resolving the effects of
conflicting selection at the within and between host levels will be
enlightening.
Figure 2. Fit of the model (red line) to data (black line). (a) The distribution of SPVL in the index partner, and (b) the recipient. Where these
roles are unknown, each individual in the pair represents half an individual in each figure. The modelled distributions were calculated from equations
(3.5) and Text S1 (5.5) for the recipient and index partner, respectively.
doi:10.1371/journal.pcbi.1002185.g002
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The pattern of mutation was modelled as a log-normal
distribution. It may be reasonable to assume that the distribution
is negatively skewed because deleterious mutations are much more
frequent than beneficial ones, for example in the case of protease
gene [42]. However, it is misleading to compare the between-host
mutation process to the mutation of individual viral genomes
because deleterious mutations may be counterbalanced by within-
host selection for viable viruses and there is no evidence for
asymmetry in the net effect.
The host effect in this study was also modelled by a log-normal
distribution which is justified if there are a large number of host effects
and they are assumed to each have a multiplicative effect on SPVL.
Host effects are known to account for a certain quantity of SPVL
variation [2,29–31,43] and a very low estimate of the environmental
variance would not be consistent with these studies. The maximum
likelihood estimate of sE was encouragingly high (sE=0.66,
Figure 1), contributing 71% of the total variance in SPVL. As
more is understood about how the host contributes to variation in
SPVL, this source of variance may be further decomposed [31].
The epidemiological component of this model could be made
more realistic. The model could for example be structured by age,
sex, location, sexual activity, HLA type and include stochastic
effects. It is not clear to us what effect on virulence these
heterogeneities will have, but they might help for example explain
Figure 3. The evolving distribution of SPVL. The SPVL distribution evolves in the population over the years since introduction of the founding
genotype. Maximum likelihood values from Figure 1 were used (sM=0.12, sE=0.66). The mean log10 SPVL of the founding genotype was (a) 3.5 and
(b) 5.5.
doi:10.1371/journal.pcbi.1002185.g003
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the persistence of diversity between subtypes and help provide
reasonable initial conditions, since a stochastic model could
elucidate which viruses are more likely to have started the
epidemic. The analysis could be further developed by relaxing the
assumption that the SPVL is at an evolutionary optimal
equilibrium, though we note that this assumption provides good
agreement with data (Figure 2). We note that the mean log10
SPVL and its heritability do not change substantially in the later
stages of the epidemic (Figure 4a–c), and the mean log10 SPVL of
the Ugandan data (4.51) is close to the predicted equilibrium value
(4.52), suggesting that even if the observed data do not represent
an equilibrium, they represent something close enough to render
the maximum likelihood parameter estimations reasonable.
Despite being simple and parsimonious rather than detailed, our
model provides a general framework that makes use of the most
recent data on the heritability of set-point viral load, and that can
be used to interpret past and predict future trends in SPVL.
One interesting trend is that the mean log10 SPVL can be
observed to increase above the equilibrium value for a short while
during the early stages of the epidemic. Epidemic growth is
expected to favour a higher virulence than at equilibrium as a
result of the cumulative advantage of rapid transmission when
hosts are abundant [19,44]. This is better demonstrated in
Figure 5(c) which shows the evolution of the mean log10 SPVL
from a founding virulence very close to the equilibrium mean. At
this level of resolution the temporary spike in virulence can be
Figure 4. Mean log10 SPVL and heritability over time. (a) Mean log10 SPVL, (b) heritability. The epidemic was run under maximum likelihood
parameter (sM= 0.12 and sE= 0.66, black), or the combination of parameters with maximum sM, consistent with high likelihood (sM= 0.39 and
sE= 0.55, red). The solid lines show runs in which the founding genotype had m= 5.5, while the dashed lines show runs with a founding genotype
with m=3.5.
doi:10.1371/journal.pcbi.1002185.g004
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seen, and this corresponds to the period of epidemic growth. As
the number of susceptible individuals grows and the epidemic
begins to slow, the virulence decreases in response towards
equilibrium as longer-lived genotypes are favoured.
This suggests that if SPVL can evolve at the between-host level
then a growing epidemic could select for higher virulence viruses.
Bolker et al. [44] model this phenomenon and suggest that the peak
of this transient virulence is likely to occur late within the first
exponential growth phase of the epidemic, so if this were observable
the virulence is likely still to be in this transient state above the
equilibrium. Whether this phenomenon has contributed to the
recent increase in virulence in Italy and the Netherlands [20,21]
cannot be distinguished from an increase in virulence as a result of
the founder having sub-optimal virulence. A future slight decrease
in virulence as an epidemic saturates would provide evidence for this
hypothesis, if it could be identified [44]. The optimum virulence
could also be shifted by a widespread intervention which affects the
nature of transmission such as circumcision, vaccination, or
antiretroviral therapy. In the current study we introduced a model
which may be used to predict such effects on virulence.
Recently published studies reporting the development of a
reasonably effective vaccine [45] and a protective vaginal gel [46]
are promising in the fight against HIV transmission. Hypothet-
ically, a vaccine may offer more protection against lower virulence
genotypes and select for more virulent ones, or vice versa. Gandon
et al. [47] produced simple models which suggested that vaccines
which target infection or transmission should have a negligible or
negative effect on virulence as reducing the rate of transmission
benefits pathogens which keep their host alive longer. However
they also modelled vaccines which reduce the growth or the
toxicity of the pathogen and suggest that this would select for
pathogens which have higher virulence which would have a
negative effect when unvaccinated individuals were infected.
Antiretroviral therapy during asymptomatic infection reduces
transmission rate [48,49], presumably by reducing viral load
[50,51]. Antiretroviral therapy would therefore modify the
relationship between SPVL, transmission and duration of
asymptomatic infection, and it is possible to construct hypothetical
scenarios that could select for either increased or decreased SPVL.
In summary, our model could be used to predict (in general terms)
the effects different interventions would have on virulence. These
changes are expected to be relatively modest compared to gains
obtained by curtailing transmission, but nonetheless some
consideration should be given to the possibility of increased
virulence and whether it could be mitigated.
Conclusion
Our results support the hypothesis that the distribution of SPVL,
and by implication of HIV-1 virulence, can plausibly be explained
by selection for increased transmission in populations, though
differences between viral subtypes needs to be elucidated in future
work. Our method disaggregates the effects of viral factors acting to
determine SPVL, the effect of mutation (and thus indirectly within-
host evolution), and other environmental and host factors. The best
estimates indicate a relatively high proportion of SPVL explained by
viral factors (26%), as well as a modest rate of evolution of putative
viral virulence factors. Reconciling these findings with data on
within-host viral evolution may yet shed further light on the role of
viral factors in HIV-1 pathogenesis.
Materials and Methods
Viral genotypes and SPVL phenotypes
In order to simplify simulations, we modelled a discrete finite set
of viral strains (‘genotype’), each capable of producing a finite
range of possible SPVL (‘phenotype’).
Each infected host in the model carries a viral genotype, i, and
has a phenotype, j. Hosts were not explicitly described in the model,
rather the model specified the dynamics of relative prevalences of
hosts infected with a virus of genotype i and phenotype j. In other
words, we used a compartmental multi-strain epidemic model.
Each genotype is defined by a predisposition to give rise to
higher or lower SPVL. Following the decomposition given by
equation (1.1), viral loads can be given as:
Vj~mizej ð2:1Þ
where ej is the environmental component (with mean zero and
variance sE
2) and mi is the component attributed to viral factors.
Figure 5. The evolution of the mean and the epidemic growth
pattern. The founding genotype has m= 4.5, very close to the
equilibrium mean, to illustrate changes in the mean in response to
growth or shrinkage of the epidemic. (a) The evolution of the mean
log10 SPVL during epidemic growth (b).
doi:10.1371/journal.pcbi.1002185.g005
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For a population of individuals infected with viral genotype i, the
mean log10 SPVL will be given by mi, which is therefore a natural
measure of the virulence of genotype i. For two viral genotypes i
and k such that i is more virulent than k, i.e. mi.mk, not all
individuals infected with genotype i will have higher SPVL than
individuals infected with genotype k, but on average they will.
The means log10 SPVL for the viral genotypes, mi, are in the range
2.0–7.0, and SPVL phenotypes, Vj, are in the range 0.0–9.0,
discretised with step 0.05 and 0.025 respectively. An individual
carrying genotype i, will have a phenotype j with a probability
denoted by fij which is taken from a normal distribution with mean mi
and variance sE
2 (2.2), normalised to sum to one for each genotype i.
fij~W Vj
mi,sE2  ð2:2Þ
Prevalence
The prevalence of infections with viral genotype i, SPVL
phenotype j, and age of infection a is represented by Yij,a(t) at time
point t. The age of infection is the time since the individual was
Figure 6. Evolution of SPVL from various scenarios of founding genotype. (a) Mean log10 SPVL over time for different founding virulences.
These range from m=2.5 to 6.5 log10 SPVL, ‘‘All’’ (red) begins with all genotypes from mi= 2.0 to 7.0 at equal prevalence, and ‘‘Equilibrium’’ (dashed
black) is the SPVL value to which all scenarios in this figure are evolving. (b) Evolution of SPVL distribution from high diversity scenario where all
genotypes are equally represented at the start, corresponding to ‘‘All’’ in panel (a). The parameter values for both are maximum likelihood values,
sM= 0.12 and sE=0.66.
doi:10.1371/journal.pcbi.1002185.g006
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infected. During the course of an infection each host passes
through three stages, primary, asymptomatic and disease (AIDS)
(P, A and D) as the age of infection a increases.
Duration of infection
Primary and disease stages have equal duration (DP and DD) and
rate of transmission (bP and bD), regardless of SPVL. Duration of
and rate of transmission during asymptomatic infection are
dependent on SPVL and the relationships were modelled as Hill
functions as fitted in Fraser et al. [19], from which the parameter
values relating to these functions were also taken (Table S1). The
mean duration of the asymptomatic stage of infection for a given
SPVL j is given by:
DA Vj
 
~
DmaxD50
Dk
Vj
DkzD50
Dk
ð2:3Þ
The progression from asymptomatic to disease stage is governed
by a survival function in Text S1 equation (5.1), in which SPj,a is
the probability of an individual with SPVL Vj remaining AIDS free
at age of infection a. This is illustrated in Figure S1.
Rate of transmission
The unadjusted rate of transmission during this stage is given
by:
b^A Vj
 
~
bmaxVj
bk
Vj
bkzb50
bk
ð2:4Þ
Rates of transmission are adjusted for duration and partner
change rate, c, in order to apply to a serial monogamy model (5.2).
Force of infection
The rate of transmission, bj,a, is given in equation (5.3) which
incorporates the different stages of infection and the curve for
survival during asymptomatic infection. The force of infection for
genotype i at time t, is calculated in equation (2.5) where Dt is the
size of the time-step.
FOIi tð Þ~
X
j
X
a
Yij,a tð Þbj,aDt ð2:5Þ
Mutation
Between generations a between-host mutation step occurs, so
the force of infection for genotype k seeds a distribution of
genotypes. The probability mik of an infection with genotype mean
mk mutating so as to seed a new infection with genotype mean mi is
taken from a normal distribution with mean mk and variance sM
2
(2.6), normalised to sum to one for each genotype k.
mik~W mijmk,sM2
  ð2:6Þ
Note that this is not mutation in the genetic sense, but rather a
measure of the change in the distribution of viral genotypes that
occurs over the course of infection within the host.
This model for the change that occurs from one infection to the
next, defined by equation (2.6), represents the simplest possible
model of the effect of within-host evolution on the distribution of
transmitted viruses. More complex models, with directional and
host-dependent selection, could feasibly be encoded in more
complex mutational matrices.
New infections in each time-step
The total number of infections for a given genotype in the next
time step, t+Dt, is calculated by the sum of the elementwise
product of each FOIk and the probability that it will mutate into
genotype i, mik. This is scaled according to X(t), the proportion of
susceptibles in the population at time t, meaning that the
genotypes are competing for the available pool of susceptibles.
To give the prevalence for each genotype and its SPVL category in
the next set of new infections (where a=0), this value is multiplied
by the probability of genotype i producing SPVL category j, fij.
Yij,0 tzDtð Þ~X tð Þfij
X
k
FOIk tð Þmik ð2:7Þ
Update infections
The prevalent infections are updated as in equation (2.8). The
term SPj,a is the function of survival from progression to AIDS,
given in equation (5.1). Since AIDS is a stage of determined
length, DD, the function of survival from death at age of infection a
is given by SPj,a{DD , the probability of surviving progression to
AIDS at a time DD years previously.
Yij,a tzDtð Þ~Yij,a tð ÞSPj,a{DD ð2:8Þ
Update susceptibles
The terms Xout(t) and Xin(t) refer to new infections and deaths,
respectively.
Xout tð Þ~
X
i
X
j
Yij,0 tð Þ ð2:9Þ
Xin tð Þ~
X
i
X
j
X
a
Yij,a tð Þ 1{SPj,a{DD
  ð2:10Þ
These are used to update the susceptible pool, with new infections
being removed and individuals who die of AIDS being replaced in
the population.
X tzDtð Þ~X tð Þ{Xout tð ÞzXin tð Þ ð2:11Þ
Calculating R0 for each genotype
The basic reproductive rate, R0, can be calculated for each
genotype, and this can be used to calculate the genotype
distribution at equilibrium using the next-generation formalism.
The R0 of each genotype is calculated in two steps. Firstly the
transmission potential is calculated for an infection with SPVL
category j by multiplying the rate of transmission in each of the
three stages of infection by the length of that stage. The duration
of asymptomatic infection DA(Vj) is the mean of the survival curve.
TPj~bPDPzbA Vj
 
DA Vj
 
zbDDD ð3:1Þ
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Secondly, the basic reproductive rate, R0i, for each genotype i, is
then calculated by taking the weighted average transmission
potential, TPj, weighted by the probability that infection with
genotype i results in infection with SPVL category j.
R0i~
X
j
TPjfij ð3:2Þ
Solution to equilibrium using next-generation formalism
The R0 for each genotype k (3.2) and the probability that
genotype k mutates into genotype i (2.6) can be used to calculate
the next-generation matrix, K.
Kik~mikR0k ð3:3Þ
The distribution of genotypes at equilibrium is the eigenvector e
corresponding to the dominant eigenvalue, l, of K.
Ke~le ð3:4Þ
The prevalence of SPVL category j, pj, at equilibrium in the
population is then calculated as follows.
p Vj
 
~
X
i
eifij ð3:5Þ
This value can then be directly compared with the observed
distribution of SPVL.
The likelihood of each run of the model is calculated by
comparison with data from a previous study reporting the SPVL of
phylogenetically confirmed transmission pairs [6] selected from a
cohort in Rakai, Uganda [52,53]. The likelihood is given by the
probability of observing the index SPVL, Vd, and the recipient’s
SPVL, Vr. This is calculated using conditional probabilities and is
given as follows. The mean log10 SPVL of the genotypes infecting
the recipient and index case are given by mx and my. As these are
unknown, all possible combinations of genotypes are considered.
p Vr\Vdð Þ~
X
x
p Vr mxjð Þ
X
y
p mx my
  b Vdð Þp Vd my p my 
C
ð3:6Þ
in which C is a constant:
C~
X
j
b Vj
 X
k
p Vj mkj
 
p mkð Þ ð3:7Þ
and the following have been previously defined in equations (2.2),
(2.6) and (3.4):
p Vr mxjð Þ~fxr ð3:8Þ
p mx my
 ~mxy ð3:9Þ
p mið Þ~ei ð3:10Þ
The total log likelihood is calculated for each couple c in which the
direction of transmission is known, and for each couple u where
the direction is unknown the log likelihood is worked out for each
direction and the mean is taken (in this case, Vm and Vf refer to
SPVL of males and females, respectively).
‘~
X
c
log p Vcr\V
c
d
  
z
X
u
1
2
log p Vum\V
u
f male donorj
  
zlog p Vuf\V
u
m female donorj
   ð3:11Þ
Calculate heritability
Heritability is the proportion of total variation which is
determined by genetic variation in the viral population. It was
measured previously by calculating the proportion of the total
variance which was explained by carrying genetically similar virus
[6]. This can be measured for the modelled distribution in a
similar fashion. The non-heritable component is the variance in
SPVL in individuals infected by an index partner with a particular
SPVL, as a proportion of total variance. This is weighted
according to each possible SPVL of the index.
h2~1{
s2Ezs
2
M
 
s2P
ð3:12Þ
s2P~
X
r
Vrð Þ2p Vrð Þ{
X
r
Vrp Vrð Þ
 !2
ð3:13Þ
Likelihood
The likelihood was estimated by calculating the total likelihood,
,total, for each combination of values of sE (range 0–1.2, step 0.005)
and sM (range 0–1.0, step 0.005). Outside of these ranges the
likelihood of observing the data is very low, as the variance of the
equilibrium distribution becomes vastly higher than is observed.
These values were used instead of their squares, sE
2 and sM
2,
because they are on the same scale as log10 SPVL and are
therefore directly related to the size of the host effect and of
between-host mutation. Furthermore, using sE and sM gives
greater resolution at lower values in the range of interest.
The values of Y0 and mıˆ were not included in this analysis as they
are not relevant to the equilibrium distribution since they serve
only as starting points in the model. All other parameter values
were taken from the literature (Table S1).
The maximum likelihood combination of these two parameters
was estimated and the 95% confidence bounds were identified
using a likelihood ratio test (5.4).
Convergence of SPVL distribution
The next-generation formalism solution described above is
sufficient for analysing the equilibrium distribution of SPVL as the
end results are identical. However, the model must be run in full to
determine the rate at which SPVL evolves in real time.
To run the model in continuous time, the infection is initialised
at time t=0 for the starting genotype ıˆ with mean mıˆ and a
proportion Y0 of the population are infected. The total number of
infected individuals at the start of the epidemic all enter genotype
category ıˆ, and are divided up between all the SPVL categories
according to fıˆj.
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Vj Yi^j,0 0ð Þ~Y0 f^ij ð4:1Þ
All other genotype categories begin at zero, (4.2), as do all ages of
infection greater than zero (4.3).
Vj ,Vk=i Ykj,0 0ð Þ~0 ð4:2Þ
Vj ,Vi,Vaw0 Yij,a 0ð Þ~0 ð4:3Þ
The model was run for 500 years in discrete time-steps
corresponding to one month for each set of the parameter values.
Parameter values, listed in Table S1, were taken from the
literature [19,54,55]. Analyses were conducted using C++,
MATLAB and R [56–58], the latter of which was also used to
produce the figures [59].
Supporting Information
Figure S1 Possible disease progression outcomes for an
infection with log10 SPVL of 6.0. All individuals have the
same length of primary and disease stage infection, regardless of
SPVL. The survival function is the border between asymptomatic
and disease stage infection (‘‘survival’’ here refers to survival from
progression to AIDS, not death). A similar pattern is seen at other
SPVL, but with a different survival function.
(TIFF)
Figure S2 Details of the likelihood surface. (a) For each
value of sM, the value of sE which gives the highest likelihood is
marked in orange on the figure, while the yellow region gives the
95% confidence bounds. Similarly, for each value of sE, the
optimum sM value is marked in dark blue, with 95% confidence
bounds in light blue. Where the maximum likelihood regions for
the two parameters overlap this is marked in green, and the point
of maximum likelihood is white. (b) Likelihood at the optimum
value of sE for each value of sM i.e. it tracks the likelihood of the
orange line. (c) Likelihood at the optimum value of sM for each
value of sE i.e. it tracks the likelihood of the dark blue line.
(TIFF)
Figure S3 Heritability of SPVL measured at equilibri-
um for each combination of parameters sM and sE. The
black line represents the border of the 95% confidence interval on
the maximum likelihood plot, Figure 1.
(TIFF)
Figure S4 Population variance of SPVL measured at
equilibrium for each combination of parameters sM and
sE. The black line represents the border of the 95% confidence
interval on the maximum likelihood plot, Figure 1.
(TIFF)
Table S1 Parameter values. Where possible these values
have been taken from the literature, and a broad range of plausible
values are applied to unknown parameters.
(DOC)
Table S2 The range of values used to construct the latin
hypercube sample. The values for each point in the hypercube
were sampled from a uniform distribution within that range.
(DOC)
Table S3 The maximum likelihood estimates of sM and
sE in 1000 bootstraps. The figures are the proportion of each
combination of values of sM and sE which were the maximum
likelihood estimate when a low resolution likelihood surface was
calculated with 1000 sets of bootstrapped parameters. These
exclude 19 bootstraps in which the optimised parameter values
gave a next-generation matrix with mixed signs, rendering the
result incalculable.
(DOC)
Table S4 The combination of parameters with the
highest value of sM in 1000 bootstraps. The figures are
the proportion of each combination of values of sM and sE which
formed the highest value of sM which was still consistent with the
95% confidence region of the maximum likelihood estimate.
Where several values of sE were available, the one with the highest
likelihood was chosen.
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